After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more_老虎社区_美港股上老虎

After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more

StreetInsider2021-12-08

After-Hours Stock Movers: Dare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

223

玉树临风英俊
·2021-12-08
👌
回复
3
举报
小虎一飞冲天
·2021-12-08
Like pls. Thanks.
回复
2
举报
收起
- 玉树临风英俊:
  Ok
  2021-12-08
  回复
  举报
HENRYCSC
·2021-12-08
Tell me your opinion about this news...
回复
3
举报
saral
·2021-12-08
Like pls thks.
回复
7
举报
收起
- PickleT68:
  Ok
  2021-12-08
  回复
  举报
WalkerWoon
·2021-12-08
Like me pls
回复
6
举报
收起
- saral:
  Sure
  2021-12-08
  回复
  举报
SC2021
·2021-12-08
Tell me your opinion about this news...
回复
4
举报
收起
- SC2021:
  Ok
  2021-12-08
  回复
  举报
SC2021
·2021-12-08
Hours
回复
4
举报
收起
- SC2021:
  Okok
  2021-12-08
  回复
  举报
vSup_puSv
·2021-12-08
Comment and like
回复
7
举报
收起
- spcenbeyond:
  ok
  2021-12-08
  回复
  举报
- vSup_puSv:
  Ty
  2021-12-08
  回复
  举报
- Gold75:
  Nice
  2021-12-08
  回复
  举报
Cub88
·2021-12-08
Good
回复
点赞
举报
OddEyeCircle
·2021-12-08
Please let me know
回复
6
举报
收起
- Tan123:
  what ?
  2021-12-08
  回复
  举报
財神發
·2021-12-08
Like w
回复
7
举报
EHG
·2021-12-08
Like
回复
5
举报
收起
- EHG:
  Ok
  2021-12-09
  回复
  举报
- Ghtan:
  Sure
  2021-12-08
  回复
  举报
Pandachubby
·2021-12-08
Lol
回复
4
举报
kdcc
·2021-12-08
Like pls.. Thanks..
回复
5
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1152070366?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-08 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152070366","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DARE","symbol_name":"Dare Bioscience","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","article_id":"1152070366","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","pubTimestamp":1638919808,"columns":[],"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"translate_title":"下班后股票搬运工：Dare Bioscience、Stitch Fix、PagerDuty、EPAM等","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DARE":0.9,"SFIX":0.9},"content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":602006191,"gmtCreate":1638935125084,"gmtModify":1638935125557,"author":{"id":"3580076354872466","authorId":"3580076354872466","name":"玉树临风英俊","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3580076354872466","authorIdStr":"3580076354872466"},"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602006191","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606778313,"gmtCreate":1638933656547,"gmtModify":1638933842310,"author":{"id":"3582098623642517","authorId":"3582098623642517","name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582098623642517","authorIdStr":"3582098623642517"},"htmlText":"Like pls. Thanks.","listText":"Like pls. Thanks.","text":"Like pls. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606778313","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6894797,"gmtCreate":1638935133893,"gmtModify":1638935134001,"authorId":3580076354872466,"author":{"id":3580076354872466,"idStr":"3580076354872466","authorId":3580076354872466,"name":"玉树临风英俊","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606778313,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":606452698,"gmtCreate":1638922701319,"gmtModify":1638922701993,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606452698","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606422407,"gmtCreate":1638922076978,"gmtModify":1638922077618,"author":{"id":"3568944508199908","authorId":"3568944508199908","name":"saral","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3568944508199908","authorIdStr":"3568944508199908"},"htmlText":"Like pls thks.","listText":"Like pls thks.","text":"Like pls thks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606422407","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6893651,"gmtCreate":1638929656317,"gmtModify":1638929656347,"authorId":3581915827887523,"author":{"id":3581915827887523,"idStr":"3581915827887523","authorId":3581915827887523,"name":"PickleT68","avatar":"https://static.tigerbbs.com/8fce28b8d12bdeb2997c5098f8b8e413","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606422407,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":606428746,"gmtCreate":1638921884643,"gmtModify":1638921884939,"author":{"id":"3567211702241491","authorId":"3567211702241491","name":"WalkerWoon","avatar":"https://static.tigerbbs.com/a772c81a4c88b39f7cdec13c1c0af077","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3567211702241491","authorIdStr":"3567211702241491"},"htmlText":"Like me pls","listText":"Like me pls","text":"Like me pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606428746","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6890989,"gmtCreate":1638922063950,"gmtModify":1638922063985,"authorId":3568944508199908,"author":{"id":3568944508199908,"idStr":"3568944508199908","authorId":3568944508199908,"name":"saral","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606428746,"type":1,"supId":0,"prevId":0,"content":"Sure","text":"Sure","html":"Sure"}],"langContent":"CN"},{"id":606464928,"gmtCreate":1638921360205,"gmtModify":1638921360674,"author":{"id":"3574796007598692","authorId":"3574796007598692","name":"SC2021","avatar":"https://static.tigerbbs.com/7db1014f5edc3cd0a7562d4262d0a5a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574796007598692","authorIdStr":"3574796007598692"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606464928","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6890739,"gmtCreate":1638921366027,"gmtModify":1638921366052,"authorId":3574796007598692,"author":{"id":3574796007598692,"idStr":"3574796007598692","authorId":3574796007598692,"name":"SC2021","avatar":"https://static.tigerbbs.com/7db1014f5edc3cd0a7562d4262d0a5a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606464928,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":606465575,"gmtCreate":1638921336957,"gmtModify":1638921337393,"author":{"id":"3574796007598692","authorId":"3574796007598692","name":"SC2021","avatar":"https://static.tigerbbs.com/7db1014f5edc3cd0a7562d4262d0a5a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574796007598692","authorIdStr":"3574796007598692"},"htmlText":"Hours","listText":"Hours","text":"Hours","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606465575","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6890742,"gmtCreate":1638921376107,"gmtModify":1638921376136,"authorId":3574796007598692,"author":{"id":3574796007598692,"idStr":"3574796007598692","authorId":3574796007598692,"name":"SC2021","avatar":"https://static.tigerbbs.com/7db1014f5edc3cd0a7562d4262d0a5a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606465575,"type":1,"supId":0,"prevId":0,"content":"Okok","text":"Okok","html":"Okok"}],"langContent":"CN"},{"id":606462250,"gmtCreate":1638921160533,"gmtModify":1638921161401,"author":{"id":"3581550492242446","authorId":"3581550492242446","name":"vSup_puSv","avatar":"https://static.tigerbbs.com/a1150421a148787160d999c5a94bed8e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581550492242446","authorIdStr":"3581550492242446"},"htmlText":"Comment and like&nbsp;","listText":"Comment and like&nbsp;","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/606462250","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6891080,"gmtCreate":1638922255904,"gmtModify":1638922255936,"authorId":3571890541915645,"author":{"id":3571890541915645,"idStr":"3571890541915645","authorId":3571890541915645,"name":"spcenbeyond","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606462250,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":6890709,"gmtCreate":1638921282904,"gmtModify":1638921282933,"authorId":3581550492242446,"author":{"id":3581550492242446,"idStr":"3581550492242446","authorId":3581550492242446,"name":"vSup_puSv","avatar":"https://static.tigerbbs.com/a1150421a148787160d999c5a94bed8e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606462250,"type":1,"supId":6890701,"prevId":0,"content":"Ty","text":"Ty","html":"Ty"},{"id":6890701,"gmtCreate":1638921270672,"gmtModify":1638921270772,"authorId":3576993112269247,"author":{"id":3576993112269247,"idStr":"3576993112269247","authorId":3576993112269247,"name":"Gold75","avatar":"https://static.tigerbbs.com/3e12eb0f20c1c6eecc3de5d5be4a1184","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606462250,"type":1,"supId":0,"prevId":0,"content":"Nice ","text":"Nice ","html":"Nice "}],"langContent":"CN"},{"id":606462622,"gmtCreate":1638921156752,"gmtModify":1638928347865,"author":{"id":"4099990080951910","authorId":"4099990080951910","name":"Cub88","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4099990080951910","authorIdStr":"4099990080951910"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606462622","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606469077,"gmtCreate":1638920760038,"gmtModify":1638920760358,"author":{"id":"3582065904370135","authorId":"3582065904370135","name":"OddEyeCircle","avatar":"https://static.tigerbbs.com/bd89742cea79ac97ec7da1a7bdbc2a14","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582065904370135","authorIdStr":"3582065904370135"},"htmlText":"Please let me know","listText":"Please let me know","text":"Please let me know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606469077","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6890902,"gmtCreate":1638921825942,"gmtModify":1638921825973,"authorId":3575263084566569,"author":{"id":3575263084566569,"idStr":"3575263084566569","authorId":3575263084566569,"name":"Tan123","avatar":"https://static.tigerbbs.com/f62a61b3de783a68b73436f05185453a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606469077,"type":1,"supId":0,"prevId":0,"content":"what ?","text":"what ?","html":"what ?"}],"langContent":"CN"},{"id":606460071,"gmtCreate":1638920717812,"gmtModify":1638920718397,"author":{"id":"4088201880010570","authorId":"4088201880010570","name":"財神發","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4088201880010570","authorIdStr":"4088201880010570"},"htmlText":"Like w","listText":"Like w","text":"Like w","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606460071","repostId":1152070366,"repostType":2,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606484389,"gmtCreate":1638920590132,"gmtModify":1638920590668,"author":{"id":"3586941861951066","authorId":"3586941861951066","name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586941861951066","authorIdStr":"3586941861951066"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/606484389","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6904883,"gmtCreate":1639007033774,"gmtModify":1639007033804,"authorId":3586941861951066,"author":{"id":3586941861951066,"idStr":"3586941861951066","authorId":3586941861951066,"name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606484389,"type":1,"supId":6890482,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6890482,"gmtCreate":1638920716602,"gmtModify":1638920716701,"authorId":3553589672555235,"author":{"id":3553589672555235,"idStr":"3553589672555235","authorId":3553589672555235,"name":"Ghtan","avatar":"https://static.tigerbbs.com/cc1760b696bc33ae7adab116832dab9e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":606484389,"type":1,"supId":0,"prevId":0,"content":"Sure","text":"Sure","html":"Sure"}],"langContent":"CN"},{"id":606485240,"gmtCreate":1638920543740,"gmtModify":1638920543977,"author":{"id":"3557300951777174","authorId":"3557300951777174","name":"Pandachubby","avatar":"https://static.tigerbbs.com/4219cbe80202ef8b5c370a68f24f052b","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3557300951777174","authorIdStr":"3557300951777174"},"htmlText":"Lol","listText":"Lol","text":"Lol","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606485240","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":606481903,"gmtCreate":1638920136350,"gmtModify":1638920136596,"author":{"id":"3582248787663478","authorId":"3582248787663478","name":"kdcc","avatar":"https://static.tigerbbs.com/6b7ab80d653c786d04ef593538824fd5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582248787663478","authorIdStr":"3582248787663478"},"htmlText":"Like pls.. Thanks..&nbsp;","listText":"Like pls.. Thanks..&nbsp;","text":"Like pls.. Thanks..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606481903","repostId":1152070366,"repostType":4,"repost":{"id":"1152070366","kind":"news","pubTimestamp":1638919808,"share":"https://www.laohu8.com/m/news/1152070366?lang=&edition=full","pubTime":"2021-12-08 07:30","market":"us","language":"en","title":"After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1152070366","media":"StreetInsider","summary":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food","content":"<p>After-Hours Stock Movers:</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.</p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/SFIX\">Stitch Fix Inc.</a> (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/PD\">PagerDuty, Inc.</a> (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/EPAM\">EPAM Systems Inc</a> (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&amp;P 500 effective prior to the opening of trading on Tuesday, December 14.</p>\n<p></p>\n<p></p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/RTX\">Raytheon Technologies Corporation</a> (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/STWD\">Starwood Property</a> (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.</p>\n<p></p>\n<p><a href=\"https://laohu8.com/S/ZTS\">Zoetis</a> (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Dare Bioscience,Stitch Fix,PagerDuty, EPAM and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-08 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19322060><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel,...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19322060\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DARE":"Dare Bioscience","SFIX":"Stitch Fix Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=19322060","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152070366","content_text":"After-Hours Stock Movers:\n\nDare Bioscience (NASDAQ: DARE) 38.5% HIGHER; announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.\n\n\nStitch Fix Inc. (NASDAQ: SFIX) 17.7% LOWER; reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $581.2 million versus the consensus estimate of $570.95 million. Stitch Fix sees Q2 2022 revenue of $505-520 million, versus the consensus of $584.7 million. Adjusted EBITDA $(5) million - $5 million\n\nPagerDuty, Inc. (NYSE: PD) 11% HIGHER; reported Q3 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $72 million versus the consensus estimate of $70.04 million. PagerDuty, Inc. sees Q4 2022 EPS of ($0.06)-($0.05), versus the consensus of ($0.08). PagerDuty, Inc. sees Q4 2022 revenue of $75.5-76.5 million, versus the consensus of $73.67 million.\n\nEPAM Systems Inc (NYSE: EPAM) 7.5% HIGHER; will replace Kansas City Southern (NYSE: KSU) in the S&P 500 effective prior to the opening of trading on Tuesday, December 14.\n\n\n\nRaytheon Technologies Corporation (NYSE: RTX) 2.3% HIGHER; Board of Directors authorized today the repurchase of up to $6 billion of the company's outstanding common stock.\n\nStarwood Property (NYSE: STWD) 2.2% LOWER; announced that subject to market and other conditions, it is offering 16,000,000 shares of its common stock in an underwritten public offering.\n\nZoetis (NYSE: ZTS) 1.5% HIGHER; announced that its Board of Directors has approved a $3.5 billion share repurchase program as part of its capital allocation plans.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":223,"commentSize":14,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}